KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Long-Term Debt Repayments (2016 - 2017)

Regeneron Pharmaceuticals has reported Long-Term Debt Repayments over the past 9 years, most recently at -$25000.0 for Q4 2017.

  • Quarterly results put Long-Term Debt Repayments at -$25000.0 for Q4 2017, up 99.67% from a year ago — trailing twelve months through Sep 2018 was -$25000.0 (down 100.2% YoY), and the annual figure for FY2017 was $19.9 million, up 290.2%.
  • Long-Term Debt Repayments for Q4 2017 was -$25000.0 at Regeneron Pharmaceuticals, up from -$37.1 million in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for REGN hit a ceiling of $159.5 million in Q4 2014 and a floor of -$144.7 million in Q4 2015.
  • Median Long-Term Debt Repayments over the past 5 years was $632000.0 (2013), compared with a mean of $13.6 million.
  • Biggest five-year swings in Long-Term Debt Repayments: soared 9558.71% in 2014 and later crashed 424.17% in 2017.
  • Regeneron Pharmaceuticals' Long-Term Debt Repayments stood at -$2.0 million in 2013, then surged by 7981.13% to $159.5 million in 2014, then plummeted by 190.68% to -$144.7 million in 2015, then skyrocketed by 94.78% to -$7.6 million in 2016, then skyrocketed by 99.67% to -$25000.0 in 2017.
  • The last three reported values for Long-Term Debt Repayments were -$25000.0 (Q4 2017), -$37.1 million (Q3 2017), and $44.1 million (Q2 2017) per Business Quant data.